1. Park JE, Hwangbo Y, Chang R, et al. Mesalazine-induced eosinophilic pneumonia in a patient with Crohn’s disease. Korean J Gastroenterol. 2009; 53:116–120.
2. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003; 9:308–315.
Article
3. Abraham A, Karakurum A. Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis. BMJ Case Rep. 2013; 2013:pii: bcr2013009834.
Article
4. Kim JH, Lee JH, Koh ES, et al. Acute eosinophilic pneumonia related to a mesalazine suppository. Asia Pac Allergy. 2013; 3:136–139.
Article
5. Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: a review of 196 case reports. Medicine (Baltimore). 2018; 97:e9688.
6. Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The groupe d'etudes et de recherche sur les maladies “orphelines” pulmonaires (GERM“O”P). Medicine (Baltimore). 1998; 77:299–312.
8. Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982; 17:389–393.
9. Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018; 47:1597–1609.
Article
10. Sesin GP, Mucciardi N, Almeida S. Mesalamine-associated pleural effusion with pulmonary infiltration. Am J Health Syst Pharm. 1998; 55:2304–2305.
Article
11. Franco AI, Escobar L, García XA, et al. Mesalazine-induced eosinophilic pneumonia in a patient with ulcerative colitis disease: a case report and literature review. Int J Colorectal Dis. 2016; 31:927–929.
Article
12. Gupta A, Gulati S. Mesalamine induced eosinophilic pneumonia. Respir Med Case Rep. 2017; 21:116–117.
Article
13. Park JY, Kang HM, Kim SY, et al. A case of mesalazine-induced eosinophilic pneumonia in a patient with ulcerative colitis. Tuberc Respir Dis. 2001; 51:474–481.
Article
14. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977; 2:892–895.
15. Kim KH, Kim TN, Jang BI. A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis. Korean J Gastroenterol. 2007; 50:379–383.
16. Borum ML, Ginsberg A. Hypersensitivity to 5-ASA Suppositories. Dig Dis Sci. 1997; 42:1076–1078.
17. Ding H, Liu XC, Mei Q, Xu JM, Hu XY, Hu J. Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. World J Gastroenterol. 2014; 20:3716–3718.
Article
18. Ji XQ, Wang LX, Lu DG. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol. 2014; 20:13501–13511.
Article